Search research articles
Contact Us
Filters
Showing results (201-210 of 316) with videos related to
Page
of 32
Sort By:
Oncotarget
|
October 30, 2016
Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors
Kieuhoa T Vo, Erin E Karski, Nicole M Nasholm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2000
Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study
M L Schmidt, J N Lukens, R C Seeger, et al.
Molecular Imaging and Biology
|
August 23, 2014
Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma
Shih-ying Huang, Wesley E Bolch, Choonsik Lee, et al.
Medical and Pediatric Oncology
|
July 24, 2001
Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma
J M Maris, C Guo, P S White, et al.
Pediatric Blood & Cancer
|
October 27, 2023
Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to <sup>131</sup> I-MIBG in patients with relapsed/refractory neuroblastoma
Vandana Batra, Ajami Gikandi, Bruce Pawel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 31, 2016
Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine
Kelly E Huibregtse, Kieuhoa T Vo, Steven G DuBois, et al.
Pediatric Blood & Cancer
|
March 27, 2015
SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings
Nehal S Parikh, Scott C Howard, Guillermo Chantada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2008
Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group
Andrew L Gilman, M Fevzi Ozkaynak, Katherine K Matthay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2000
Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study
H J Nickerson, K K Matthay, R C Seeger, et al.
EJNMMI Research
|
June 13, 2024
Aurora Kinase A inhibition enhances DNA damage and tumor cell death with <sup>131</sup>I-MIBG therapy in high-risk neuroblastoma
Prerna Kumar, Jessica Koach, Erin Nekritz, et al.
Page
of 32
Search research articles
Search
Showing results (201-210 of 316) with videos related to
Sort By:
Page
of 32
Oncotarget
|
October 30, 2016
Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors
Kieuhoa T Vo, Erin E Karski, Nicole M Nasholm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2000
Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study
M L Schmidt, J N Lukens, R C Seeger, et al.
Molecular Imaging and Biology
|
August 23, 2014
Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma
Shih-ying Huang, Wesley E Bolch, Choonsik Lee, et al.
Medical and Pediatric Oncology
|
July 24, 2001
Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma
J M Maris, C Guo, P S White, et al.
Pediatric Blood & Cancer
|
October 27, 2023
Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to <sup>131</sup> I-MIBG in patients with relapsed/refractory neuroblastoma
Vandana Batra, Ajami Gikandi, Bruce Pawel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 31, 2016
Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine
Kelly E Huibregtse, Kieuhoa T Vo, Steven G DuBois, et al.
Pediatric Blood & Cancer
|
March 27, 2015
SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings
Nehal S Parikh, Scott C Howard, Guillermo Chantada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2008
Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group
Andrew L Gilman, M Fevzi Ozkaynak, Katherine K Matthay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2000
Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study
H J Nickerson, K K Matthay, R C Seeger, et al.
EJNMMI Research
|
June 13, 2024
Aurora Kinase A inhibition enhances DNA damage and tumor cell death with <sup>131</sup>I-MIBG therapy in high-risk neuroblastoma
Prerna Kumar, Jessica Koach, Erin Nekritz, et al.
Page
of 32